Across TCGA pan-cancer cohorts, ZBTB37 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZBTB37 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher ZBTB37 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ZBTB37 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

GBM, UCEC, and LUAD are the cancer types where ZBTB37 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Tertile	All	0.471	0.731	.007	9	view →
UCEC	DFS	Quartile	All	0.765	1.000	.005	6	view →
LUAD	OS	Tertile	All	1.000	0.946	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ZBTB37 tumor-vs-normal RNA expression · all ZBTB37 data types